Status and phase
Conditions
Treatments
About
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
Full description
PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.
Randomization and blinding: This is a randomized, controlled, open-label study and blinding is not applicable to this study.
Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female at least 18 years of age.
Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml.
Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market.
Sequential Organ Failure Assessment (SOFA) score ≥ 5
Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:
Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline.
Receiving vasopressors to maintain the target MAP of 65 mmHg.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
46 participants in 1 patient group
Loading...
Central trial contact
Cuthbert O Simpkins, MD, FACS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal